NYSE:SER
Serina Therapeutics, Inc.
Serina Therapeutics, Inc.'s revenue grew 132.1% in fiscal 2025 to $130,000 while operating margin rose to −18478.5%. Free cash flow was −$18.0M, −13856.9% of revenue, and the diluted share count rose 38.5%.Summary generated from Serina Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$130,000
Revenue growth+132.1%
Revenue, 5-yr CAGR−18.5%
Gross marginn/a
Operating margin−18478.5%
Net margin−14755.4%
ROICn/a
Return on equity−6351.7%
Debt / equityn/a
Free cash flow−$18.0M
FCF margin−13856.9%
Share count change+38.5%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3 | 0 | 0 |
| Operating income | −8 | −7 | −3 | −17 | −24 |
| Net income | −9 | −10 | 5 | −11 | −19 |
| Free cash flow | n/a | n/a | −3 | −17 | −18 |
Recent filings
- 8-KAmendment to articles or bylaws
Oct 9, 2026 - 8-KOther events
Sep 9, 2026 - 8-KEntry into a material agreement
Aug 27, 2026 - S-1Registration statement
Aug 24, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 4Insider transaction report
Jul 23, 2026 - 8-KDirector or officer change
Jul 23, 2026